Table 2.

Multivariate-adjusted HRs for the development of type 2 diabetes associated with metabolic syndrome and its individual components

	Population at risk (n)	No. events	Multivariate-adjusted HR (95% CI)	P
Men
Updated 2005 NCEP ATP III
(−)	597	82	1 (referent)
(+)	196	63	2.58 (1.85–3.59)	<0.001
IFG
(−)	401	35	1 (referent)
(+)	392	110	3.76 (2.57–5.52)	<0.001
Central obesity
(−)	667	103	1 (referent)
(+)	126	42	2.28 (1.58–3.29)	<0.001
Reduced HDL cholesterol
(−)	614	108	1 (referent)
(+)	179	37	1.32 (0.90–1.95)	0.16
Elevated triglycerides
(−)	579	84	1 (referent)
(+)	214	61	2.05 (1.46–2.88)	<0.001
Elevated blood pressure
(−)	338	41	1 (referent)
(+)	455	104	2.17 (1.49–3.17)	<0.001
Women
Updated 2005 NCEP APT III
(−)	723	52	1 (referent)
(+)	419	89	3.69 (2.58–5.27)	<0.001
IFG
(−)	685	47	1 (referent)
(+)	457	94	3.50 (2.45–5.00)	<0.001
Central obesity
(−)	496	39	1 (referent)
(+)	646	102	1.96 (1.35–2.85)	<0.001
Reduced HDL cholesterol
(−)	631	64	1 (referent)
(+)	511	77	1.55 (1.10–2.18)	0.01
Elevated triglycerides
(−)	973	105	1 (referent)
(+)	169	36	2.28 (1.54–3.37)	<0.001
Elevated blood pressure
(−)	598	51	1 (referent)
(+)	544	90	2.49 (1.74–3.58)	<0.001

Data are n or HR (95% CI). IFG, FPG levels of 5.6–6.9 mmol/l; central obesity, waist circumference of ≥90 cm in men and ≥80cm in women; reduced HDL cholesterol, HDL cholesterol levels of <1.03 mmol/l in men and <1.29 mmol/l in women; elevated triglycerides, triglyceride levels of ≥1.68 mmol/l; elevated blood pressure, blood pressure ≥130/85 mmHg and/or current use of antihypertension agents. Multivariate adjustment was made for age, family history of diabetes, total cholesterol, alcohol intake, smoking habits, and regular exercise.